Dayou Ma

Dr. Dayou Ma

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YXYuanzhu Xie
Yuanzhu Xie
SZShuaiwen Zhu
Shuaiwen Zhu
LCLing Chen
Ling Chen
HLHongdou Liu
Hongdou Liu
TPTing Peng
Ting Peng
ZLZhiyong Luo
Zhiyong Luo
Background: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, with shorter five-year survival than other breast cancer subtypes, and lacks targeted and hormonal treatment strategies. The signal transducer and activator of transcription 3 (STAT3) signaling is up-regulated in various tumors, including TNBC, and plays a vital role in regulating the expression of multiple proliferation- and apoptosis-related genes. Results: By combining the unique structures of the natural compounds STA-21 and Aulosirazole with antitumor activities, we synthesized a class of novel isoxazoloquinone derivatives and showed that one of these compounds, ZSW, binds to the SH2 domain of STAT3, leading to decreased STAT3 expression and activation in TNBC cells. Furthermore, ZSW promotes STAT3 ubiquitination, inhibits the proliferation of TNBC cells in vitro, and attenuates tumor growth with manageable toxicities in vivo. ZSW also decreases the mammosphere formation of breast cancer stem cells (BCSCs) by inhibiting STAT3. Conclusions: We conclude that the novel isoxazoloquinone ZSW may be developed as a cancer therapeutic because it targets STAT3, thereby inhibiting the stemness of cancer cells.

16 August 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LCLing Chen
Ling Chen
LWLiuliu Wang
Liuliu Wang
JGJinlei Gao
Jinlei Gao
YXYuanzhu Xie
Yuanzhu Xie
XDXu Deng
Xu Deng
SLSuyou Liu
Suyou Liu

15 August 2025 in Hepatology Communications
Verified
Journal Article
Open access
ZMZhengnan Ming
Zhengnan Ming
TLTiao Luo
Tiao Luo
ZZZi-Zheng Zou
Zi-Zheng Zou
WLWensong Luo
Wensong Luo
XHXiyuan Hu
Xiyuan Hu
ZLZhiyong Luo
Zhiyong Luo
Background: The urea cycle and pyrimidine synthesis occur mainly in the liver and undergo opposite changes during hepatocarcinogenesis. Argininosuccinate synthase 1 (ASS1) and carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) are key enzymes in the urea cycle and pyrimidine synthesis, respectively, and compete for the common substrate, aspartate. Moreover, ASS1 is lowly expressed in certain cancers, while CAD is highly expressed. However, the role of ASS1 and CAD in liver cancer still remains unclear. Methods: ASS1 and CAD expression in liver cancer were detected by tissue microarrays. Overexpression of ASS1 and CAD was achieved via lentivirus methods. All in vitro experiments were conducted in cells. The interactions of ASS1 and CAD were detected by co-immunoprecipitation (Co-IP) and GST-pull down. The in vivo study was conducted in a BALB/c nude mouse model. Intracellular metabolites were detected by LC–MS/MS. Results: ASS1 was lowly expressed in liver cancer, while CAD was highly expressed. In patients with recurrent liver cancer, ASS1 and CAD were significantly negatively correlated. Moreover, liver cancer patients with low ASS1 expression and high CAD expression had a poor prognosis. ASS1 and CAD interacted directly and promoted CAD ubiquitination through STUB1. In addition, Overexpression of CAD attenuated the tumor-suppressive effect of ASS1 in liver cancer cells. Pyrimidine supplementation enhanced the growth of liver cancer cells with ASS1 overexpression. Conclusions: ASS1 deficiency causes an imbalance in the urea cycle and pyrimidine synthesis in liver cancer. ASS1 directly controls the ubiquitination of CAD via STUB1, rather than just competing with aspartate, thereby suppressing liver cancer. Thus, ASS1 has potential as a druggable target in liver cancer.

1 November 2015 in Industrial Crops and Products
Verified
Journal Article
Closed access
SLSuyou Liu
Suyou Liu
FXFei Xu
Fei Xu
LLLijun Liu
Lijun Liu
DMDayou Ma
Dayou Ma

10 June 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZSZhongtai Sui
Zhongtai Sui
MLMo Li
Mo Li
XWXueyi Wang
Xueyi Wang
CLCailin Luo
Cailin Luo
LCLing Chen
Ling Chen
DMDayou Ma
Dayou Ma

6 November 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XDXu Deng
Xu Deng
YLYao Li
Yao Li
LCLing Chen
Ling Chen
YXYuanzhu Xie
Yuanzhu Xie
XLXiaohe Liu
Xiaohe Liu
DMDayou Ma
Dayou Ma